AlzeCure Pharma AB, listed on Nasdaq First North Premier Growth Market, is a pharmaceutical company focusing on the research and development of innovative and effective treatments for Alzheimer's disease and related disorders.
The board of directors for AlzeCure Pharma has resolved a rights issue of approximately SEK 53 million. In addition,the board may exercise an over-allotment option of up to SEK 15 million. The rights issue is subject to approval of the general meeting of shareholders.
Synch Advokat is AlzeCure Pharma's legal advisor in the transaction, and Zonda Partners is its financial advisor. Synch's team comprises Mattias Anjou, Olof Hultén, and Clara Löfgren.
Synch is a business-oriented law firm with innovation and technology at its heart. Our mission is to bring calm to any legal question, no matter the challenge. We do this by providing advisory services and packaged solutions that make the best use of technology. With true passion and dedication, we help our clients on their entire journey – from start to exit and beyond.
